New genetic test reveals whether or not you'd benefit from chemotherapy

A new marvel of medical science:

Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

The Prosigna test, made by the global diagnostics company Veracyte, analyses the activity of 50 genes in tumour tissue. It determines the molecular subtype and provides a score revealing the risk of breast cancer returning in the next decade, helping doctors decide if chemotherapy is worthwhile or not.

The test returns a score. The study showed that if the score was low then having chemotherapy - a famously unpleasant process to go through- had no significant positive benefit.

Five years after treatment, 95% of those who had chemotherapy and hormone therapy were alive and free from breast cancer recurrence, while 94% of those who skipped chemotherapy were also alive and recurrence-free.